Design Therapeutics DSGN 深 沪
等待开盘 10-11 09:30:00 美东时间
6.75
-0.370
-5.20%
华盛通- 最 高7.13
- 今 开7.13
- 成交量 40.40万股
- 最 低 6.39
- 昨 收 7.12
- 总市值 3.84亿
- 52周最高 7.77
- 市盈率 静 --
- 换手率 0.71%
- 52周最低 2.60
- 委 比 0.84%
- 总股本 5694.81万
- 历史最高 50.50
- 量 比 2.79
- 振 幅 10.39%
- 历史最低 1.94
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Design Therapeutics Appoints Justin Gover as Director
An update from Design Therapeutics ( ($DSGN) ) is now available. On September 9...
09-11 04:38
Design Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics announced the appointment of Justin Gover to its Board of Directors, effective immediately. With over 25 years of leadership experience, Gover previously served as CEO of GW Pharmaceuticals, where he led the company's growth and successful $7 billion acquisition by Jazz Pharmaceuticals. Dr. Arsani William, who joined the Board in 2021, has stepped down, with his tenure contributing significantly to the company's progress, incl...
09-10 20:01
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller
Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns.
08-30 00:42
Design Therapeutics Reports Increased R&D Expenses Amid Net Loss
Design Therapeutics, Inc. ( ($DSGN) ) has released its Q2 earnings. Here is a b...
08-20 11:54
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold
Design Therapeutics ( ($DSGN) ) has issued an announcement. On August 7, 2025, ...
08-08 04:46
Design Therapeutics Q2 EPS $(0.34) Misses $(0.33) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 61.9 percent decrease over losses of $(0.21) per share
08-08 04:43
Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenous Infusion In Its RESTORE-FA Open-label Phase 1/2 Multiple-ascending Dose Trial Of Dt-216P2, Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Demonstrated Favorable Safety and Pharmacokinetics
The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IV and subcutaneous administration of DT-216P2 in patients with FA. DT-216P2 has been
06-04 19:03
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Design Therapeutics announced the dosing of the first Friedreich ataxia patient with DT-216P2 in its RESTORE-FA Phase 1/2 trial, with no adverse events reported. The trial is ongoing in Australia, and data on FXN expression after 12 weeks of dosing is expected in 2026. The company submitted an IND application to expand the trial to U.S. sites but received a clinical hold notice from the FDA due to nonclinical deficiencies. Initial data from a Pha...
06-04 11:00
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
Design Therapeutics, a biotechnology company developing therapies for genetic diseases, announced its participation in the 2025 Jefferies Global Healthcare Conference. Management will present on June 4, 2025, with a live webcast available via the company’s website. The company focuses on GeneTAC® platform-based therapies targeting gene expression to address genetic diseases, with ongoing programs for conditions like Friedreich ataxia and Huntingt...
05-28 12:00
Design Therapeutics Q1 EPS $(0.31) Misses $(0.28) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 55 percent decrease over losses of $(0.20) per share
05-08 04:46
